OncoMatch/Clinical Trials/NCT05318027

ChatBot and Activity Monitoring in Patients Undergoing Chemoradiotherapy

Is NCT05318027 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies ChatBot for lung cancer.

Phase 2RecruitingAbramson Cancer Center at Penn MedicineNCT05318027Data as of May 2026

Treatment: ChatBot — Evaluate the feasibility of using a chatbot combined with continuous activity monitoring to proactively identify, appropriately triage and help manage patients' symptoms during cancer treatment Determine whether such an early outpatient clinic-based intervention can decrease rates of excess triage visits Correlate changes in activity and early symptom management to emergency department visits, unplanned inpatient hospitalizations and treatment breaks

Check if I qualify

Extracted eligibility criteria

Cancer type

Non-Small Cell Lung Carcinoma

Colorectal Cancer

Gastric Cancer

Hepatocellular Carcinoma

Pancreatic Cancer

Cholangiocarcinoma

Esophageal Carcinoma

Head and Neck Squamous Cell Carcinoma

Performance status

ECOG 0–3(Limited self-care)

Structured fields extracted by AI. May contain errors — verify against the official protocol.

US trial sites

Abramson Cancer Center of the University of Pennsylvania · Philadelphia, Pennsylvania

Showing up to 5 US sites. See all sites on ClinicalTrials.gov →

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify